2020
Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma
Middleton MR, McAlpine C, Woodcock VK, Corrie P, Infante JR, Steven NM, Evans TRJ, Anthoney A, Shoushtari AN, Hamid O, Gupta A, Vardeu A, Leach E, Naidoo R, Stanhope S, Lewis S, Hurst J, O’Kelly I, Sznol M. Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma. Clinical Cancer Research 2020, 26: 5869-5878. PMID: 32816891, PMCID: PMC9210997, DOI: 10.1158/1078-0432.ccr-20-1247.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAtaxia Telangiectasia Mutated ProteinsCD3 ComplexCD8-Positive T-LymphocytesCell ProliferationChemokine CXCL10Cytotoxicity, ImmunologicDisease-Free SurvivalFemaleGene Expression Regulation, NeoplasticGp100 Melanoma AntigenHumansImmunityInterferon-gammaMaleMelanomaMiddle AgedNeoplasm ProteinsReceptors, Antigen, T-CellReceptors, CXCR3Recombinant Fusion ProteinsTumor MicroenvironmentConceptsT cellsBispecific fusion proteinMetastatic melanomaT cell receptorSerum CXCL10Multicenter phase I/II trialPhase I/II trialTreatment-related adverse eventsHigh-affinity T-cell receptorsAppearance of rashMetastatic cutaneous melanomaAntitumor immune responseOverall survival rateMetastatic uveal melanomaCytotoxic T cellsPathway-related markersTumor biopsy samplesMechanism of actionII trialAdverse eventsAdvanced melanomaBroad therapeutic potentialPatient survivalPatient cohortCutaneous melanoma
2017
Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer
Zloza A, Karolina Palucka A, Coussens LM, Gotwals PJ, Headley MB, Jaffee EM, Lund AW, Sharpe AH, Sznol M, Wainwright DA, Wong KK, Bosenberg MW. Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer. Journal For ImmunoTherapy Of Cancer 2017, 5: 77. PMID: 28923102, PMCID: PMC5604351, DOI: 10.1186/s40425-017-0278-6.Peer-Reviewed Original ResearchConceptsImmunotherapy of cancerCancer immunologyHumanized modelImmunotherapy researchImmune-targeted therapiesAntitumor immune responseCancer immunotherapy researchCancer immunotherapyImmune responseMurine modelMouse modelImmunotherapyPredictive valueSubsequent panel discussionNational HarborAnnual MeetingImmunologyDrug developmentCancerMiceFuture directionsImmunocompetentTherapyCancer modeling
2013
Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer
Sznol M, Chen L. Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer. Clinical Cancer Research 2013, 19: 1021-1034. PMID: 23460533, PMCID: PMC3702373, DOI: 10.1158/1078-0432.ccr-12-2063.Peer-Reviewed Original ResearchConceptsB7-H1PD-1PD-1/PDAnti-PD-1 antibodyTumor microenvironmentAccurate predictive biomarkersEncouraging safety profileLigand B7-H1Antitumor immune responseB7-H1 expressionSubset of patientsImmune suppressive moleculesT cell functionInitial clinical studiesActivated T lymphocytesAdvanced human cancersRemarkable antitumor activityB7-DCClinical responseMetastatic diseaseDeath-1Immune suppressionSafety profileLung cancerPredictive biomarkers
2009
Betting on immunotherapy for melanoma
Sznol M. Betting on immunotherapy for melanoma. Current Oncology Reports 2009, 11: 397-404. PMID: 19679015, DOI: 10.1007/s11912-009-0053-z.Peer-Reviewed Original ResearchConceptsAdvanced melanomaAntigen-specific T cell expansionEffective antitumor immune responseAntitumor immune responseEffective treatment optionT cell expansionAntigen-specific lymphocytesTumor defense mechanismsDurable remissionsPreparative regimensConditioning regimensAdoptive immunotherapyImmune therapyCancer vaccinesImmune activationTreatment optionsPredictive biomarkersPrimary tumorTumor immunobiologyClinical trialsAntigen presentationImmune responseHigh riskNew cytokinePatients